What are the guidelines for using biologics in pediatric patients?
de Zoeten
Edwin
E
Division of Gastroenterology, Hepatology, & Nutrition, Children's Hospital of Philadelphia, Pennsylvania, USA.
Mamula
Petar
P
D000367:Age Factors; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D001691:Biological Therapy; D002648:Child; D019317:Evidence-Based Medicine; D006128:Growth / Q000187:drug effects; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000628:therapy*; D000069285:Infliximab; D010372:Pediatrics / Q000592:standards*; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab